HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

08 Sep, 2021

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
Photo by Sarah Elizabeth on Unsplash

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: